| Literature DB >> 18446509 |
Jarkko Rautio1, Krista Laine, Mikko Gynther, Jouko Savolainen.
Abstract
Central nervous system (CNS) drug delivery remains a major challenge, despite extensive efforts that have been made to develop novel strategies to overcome obstacles. Prodrugs are bioreversible derivatives of drug molecules that must undergo an enzymatic and/or chemical transformation in vivo to release the active parent drug, which subsequently exerts the desired pharmacological effect. In both drug discovery and drug development, prodrugs have become an established tool for improving physicochemical, biopharmaceutical or pharmacokinetic properties of pharmacologically active agents that overcome barriers to a drug's usefulness. This review provides insight into various prodrug strategies explored to date for CNS drug delivery, including lipophilic prodrugs, carrier- and receptor-mediated prodrug delivery systems, and gene-directed enzyme prodrug therapy.Mesh:
Substances:
Year: 2008 PMID: 18446509 PMCID: PMC2751454 DOI: 10.1208/s12248-008-9009-8
Source DB: PubMed Journal: AAPS J ISSN: 1550-7416 Impact factor: 4.009